[Childhood rhabdomyosarcoma].
Overall five-year survival of Childhood rhabdomyosarcoma (RMS) is reported to be 70% in the Intergroup Rhabdomyosarcoma Study Group (IRSG), however, the figure in Japan is almost 15% lower than that of IRSG. Treatment regimen of RMS essentially depends on the histology of the tumor, site, preoperative staging and postoperative grouping that leads to the risk classification. VAC is a standard chemotherapeutic regimen for low and intermediate risk group. Clinical trial with CPT-11 or high dose chemotherapy are underway for high risk RMS.
Morikawa
Yasuhide
Y
Pediatric Surgery, Keio University School of Medicine, Tokyo, Japan.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D002648:Child; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003609:Dactinomycin / Q000008:administration & dosage; D006801:Humans; D000077146:Irinotecan; D011879:Radiotherapy Dosage; D012208:Rhabdomyosarcoma / Q000145:classification / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery*; D012306:Risk; D014750:Vincristine / Q000008:administration & dosage
D003609:Dactinomycin; D014750:Vincristine; D000077146:Irinotecan; D003520:Cyclophosphamide; D002166:Camptothecin